lansoprazole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 60 Diseases   42 Trials   42 Trials   1101 News 


12345678910111213...1920»
  • ||||||||||  Journal:  Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan. (Pubmed Central) -  Feb 21, 2025   
    We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan...The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital's adopted medication...Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ?2 hypomagnesemia did not reappear later. This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.
  • ||||||||||  Clinical, Retrospective data, Review, Journal:  Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. (Pubmed Central) -  Feb 20, 2025   
    This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial. The bismuth quadruple therapies recommended by the guidelines for the treatment of H. Pylori have good performance in terms of four-week eradication rate and safety outcome indicators, and due to the different resistance of antibiotics in different regional populations, rational use of drugs should be combined with local conditions.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
    Journal, Adverse events:  Cyclin-dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. (Pubmed Central) -  Feb 3, 2025   
    Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation...For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter...Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
  • ||||||||||  Journal:  Proton pump inhibitors and all-cause mortality risk among cancer patients. (Pubmed Central) -  Jan 27, 2025   
    These findings emphasize the need for cautious use of PPIs in cancer patients and suggest that alternative treatments should be considered when clinically feasible. However, further studies are needed to corroborate our findings, given the significant adverse outcomes in cancer patients.
  • ||||||||||  Journal:  Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians. (Pubmed Central) -  Jan 12, 2025   
    The case illustrates that bariatric surgery is an effective and safe operation for people living with HIV. Due to complex needs and the need for regular follow-up; primary care, family, and HIV physicians can all collaborate in the care of individuals living with HIV and who underwent bariatric surgery.
  • ||||||||||  Review, Journal:  Peptic Ulcer Disease: A Review. (Pubmed Central) -  Dec 3, 2024   
    Acid blocking with proton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment. Recurrence of ulcers can be prevented by eradicating H pylori if present and discontinuing aspirin or NSAIDs if applicable.
  • ||||||||||  Journal:  Association between proton pump inhibitors and dementia risk: a Mendelian randomization study. (Pubmed Central) -  Nov 20, 2024   
    Additionally, FTD was found to reversely increase rabeprazole use (OR 1.086; 95% CI 1.011-1.167; p?=?0.023)...Our study indicates no robust causality between PPI use and increased dementia risk. Thus, it is inappropriate to restrict clinically justified PPI prescriptions merely due to potential cognitive risks.
  • ||||||||||  lansoprazole / Generic mfg., clarithromycin / Generic mfg., amoxicillin / Generic mfg.
    Trial completion date, Trial primary completion date:  A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile (clinicaltrials.gov) -  Nov 17, 2024   
    P=N/A,  N=500, Recruiting, 
    Thus, it is inappropriate to restrict clinically justified PPI prescriptions merely due to potential cognitive risks. Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Apr 2024 --> Oct 2025
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  ARMV: Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment (clinicaltrials.gov) -  Nov 17, 2024   
    P=N/A,  N=74, Recruiting, 
    Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Apr 2024 --> Oct 2025 Not yet recruiting --> Recruiting | Trial completion date: Aug 2027 --> Dec 2028 | Initiation date: Apr 2024 --> Sep 2024 | Trial primary completion date: Apr 2027 --> Dec 2025
  • ||||||||||  PK/PD data, Review, Journal:  Proton Pump Inhibitors in Patients with Cirrhosis: Pharmacokinetics, Benefits and Drawbacks. (Pubmed Central) -  Oct 22, 2024   
    It underscores the need for careful risk-benefit assessments and exploration of alternative therapies. Future research should aim to identify safer management strategies for portal hypertension complications and to develop evidence-based guidelines for PPI use in patients with cirrhosis.
  • ||||||||||  Jaqbo (zastaprazan) / Jeil
    Trial completion, Trial completion date, Trial primary completion date:  Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer (clinicaltrials.gov) -  Aug 25, 2024   
    P3,  N=329, Completed, 
    (ClinicalTrials.gov, NCT02679508.). Not yet recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> Jul 2024
  • ||||||||||  lansoprazole / Generic mfg., clarithromycin / Generic mfg., amoxicillin / Generic mfg.
    A Rare Case of Non- pylori Helicobacter Gastritis from Feline Mouth-to-Mouth CPR (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3889;    
    Treatment with similar regimens for H. pylori appears effective in eradicating H. heilmanii . Figure: Diff-Quick stain showing numerous spiraled-shaped microorganisms consistent with H. heilmannii (400x)
  • ||||||||||  Voquezna (vonoprazan) / Takeda, Phathom Pharma
    Rash Decisions: An Unexpected Consequence of PPI Use (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2816;    
    In cases similar to this patient, desensitization to PPI or alternative treatments such as vonoprazan may be more suitable...Counseling patients on such effects increases their awareness to seek immediate medical attention. Figure: Rare skin rash following pantoprazole initiation
  • ||||||||||  Journal:  Effect of proton pump inhibitors on susceptibility and melanogenesis of Sporothrix species. (Pubmed Central) -  Aug 15, 2024   
    As for the inhibition of melanogenesis, only OMP showed inhibition, with a 54% reduction.Conclusion. It concludes that the PPIs OMP and RBP have antifungal activity in vitro against planktonic cells and biofilms of Sporothrix species and that, in addition, OMP can inhibit the melanization process in Sporothrix species.